Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Related Keywords

Astellas Pharma ,Sandesh Seth ,Matthew Beck ,Prnewswire Actinium Pharmaceuticals Inc ,Oncology Lg Chem Life Sciences ,Actinium Pharmaceuticals Inc ,Actimaba Program Expansion ,Investor Relations Communications ,Exchange Commission ,Actimaba National Cancer Institute ,Novartis ,Society Of Hematologic Oncology ,Hematologic Oncology ,Study Results ,Overall Survival ,Deep Responses ,Prolonged Survival ,Adverse Risk Acute Myeloid Leukemia ,Received Prior Venetoclax ,Actinium Chairman ,Program Expansion ,Antileukemic Activity ,Preclinical Model ,National Cancer Institute ,Life Sciences ,Actinium Pharmaceuticals ,Nc ,